Capricor Therapeutics ($CAPR) has entered into a long-term lease agreement to massivelly upsize their operations beginning in 2027, with a long abatement period to allow build out of facilities. The $170 million structure is fully turn-key with ability to quickly scale, a former Takeda Pharmaceuticals property. [https://www.stocktitan.net/sec-filings/CAPR/8-k-capricor-therapeutics-inc-reports-material-event-aa3271ede72f.html](https://www.stocktitan.net/sec-filings/CAPR/8-k-capricor-therapeutics-inc-reports-material-event-aa3271ede72f.html)
This is the strongest sign yet of FDA approval, as no one would ever enter into such a strong lease agreement with FDA contingencies if a forthcoming approval or insight was not known. As a result, I've re-entered at 400% higher than my last purchase $20.75 and have bought 100,000 shares and sold $30 covered call options for $5.30 for August. A nice 75% return potential in 30 days.
